Chondrosarcoma: H1 2018 Pipeline Review with Therapeutics Development & Assessment, Companies Involved, and Drug Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Chondrosarcoma - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology).
Key Topics CoveredIntroduction Chondrosarcoma - Overview Chondrosarcoma - Therapeutics Development Chondrosarcoma - Therapeutics Assessment Chondrosarcoma - Companies Involved in Therapeutics Development Chondrosarcoma - Drug Profiles Chondrosarcoma - Discontinued Products Chondrosarcoma - Product Development Milestones Appendix
Companies MentionedAgios Pharmaceuticals Inc Daiichi Sankyo Co Ltd Epizyme Inc Horizon Pharma Plc Idera Pharmaceuticals Inc Karyopharm Therapeutics Inc Merck & Co Inc Nektar Therapeutics Novartis AG Ono Pharmaceutical Co Ltd Pfizer Inc
For more information about this report visit https://www.researchandmarkets.com/research/tqhnwk/chondrosarcoma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006494/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/05/2018 02:01 PM/DISC: 06/05/2018 02:01 PM